

UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER OF PATENTS AND TRADEMARKS Washington, D.C. 20231 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
09/181,027	10/27/1998	THOMAS HAAF	A-65680-4/RF	9418
75	590 04/04/2002			
FLEHR HOHBACH TEST			EXAMINER	
ALBRITTON & HERBERT FOUR EMBARCADERO CENTER SUITE 3400 SAN FRANCISCO, CA 94111			BRUSCA, JOHN S	
			ART UNIT	PAPER NUMBER
Or in the intent	,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,		1631	
			DATE MAILED: 04/04/2002	17

Please find below and/or attached an Office communication concerning this application or proceeding.

· · · · · · · · · · · · · · · · · · ·						
		Application No.	Applicant(s)			
Office Action Summany		09/181,027	HAAF ET AL.			
	Office Action Summary	Examiner	Art Unit			
		Brusca S John	1631			
	The MAILING DATE of this communication appears on the cover she t with the correspondence address Period for Reply					
A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) FROM THE MAILING DATE OF THIS COMMUNICATION. - Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication. - If the period for reply specified above is less than thirty (30) days, a reply within the statutory minimum of thirty (30) days will be considered timely. - If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication. - Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). - Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).						
Status	December 4. communication (a) filed as 00.5	- h				
1)⊠						
2a)⊠	This action is FINAL . 2b) ☐ This action is non-final.					
3) Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under <i>Ex parte Quayle</i> , 1935 C.D. 11, 453 O.G. 213.						
Disposition of Claims						
4)⊠ Claim(s) <u>40-45 and 47-55</u> is/are pending in the application.						
4a) Of the above claim(s) <u>45</u> is/are withdrawn from consideration.						
5) Claim(s) is/are allowed.						
6)⊠ Claim(s) <u>40-44 and 47-55</u> is/are rejected.						
7) 🗌	Claim(s) is/are objected to.					
8)□	Claim(s) are subject to restriction and/or	r election requirement.				
Application Papers						
9) The specification is objected to by the Examiner.						
10) 🔲 🗆	Fhe drawing(s) filed on is/are: a)☐ accep	oted or b)⊡ objected to by the Exa	miner.			
_	Applicant may not request that any objection to the					
11) 🗌 -	The proposed drawing correction filed on		oved by the Examiner.			
If approved, corrected drawings are required in reply to this Office action.						
12)☐ The oath or declaration is objected to by the Examiner.						
Priority under 35 U.S.C. §§ 119 and 120						
13) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).						
a)[☐ All b) ☐ Some * c) ☐ None of:					
	1. Certified copies of the priority documents	s have been received.				
2. Certified copies of the priority documents have been received in Application No						
 3. Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)). * See the attached detailed Office action for a list of the certified copies not received. 						
14)⊠ Acknowledgment is made of a claim for domestic priority under 35 U.S.C. § 119(e) (to a provisional application).						
a) The translation of the foreign language provisional application has been received. 15) Acknowledgment is made of a claim for domestic priority under 35 U.S.C. §§ 120 and/or 121.						
Attachment(s)						
1) Notice of References Cited (PTO-892) 2) Notice of Draftsperson's Patent Drawing Review (PTO-948) 3) Information Disclosure Statement(s) (PTO-1449) Paper No(s)						

Application/Control Number: 09/181,027

Art Unit: 1631

DETAILED ACTION

Continued Prosecution Application

1. The request received on 28 February 2002 for a Continued Prosecution Application (CPA) under 37 CFR 1.53(d) based on parent Application No. 09/181027 is acceptable and a CPA has been established. An action on the CPA follows.

Election/Restrictions

2. This application contains claim 45 drawn to an invention nonelected with traverse in Paper No. 6. A complete reply to the final rejection must include cancellation of nonelected claims or other appropriate action (37 CFR 1.144) See MPEP § 821.01.

Claim Rejections - 35 USC 112

- 3. The following is a quotation of the first paragraph of 35 U.S.C. 112:
 - The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same and shall set forth the best mode contemplated by the inventor of carrying out his invention.
- 4. The rejection of claims 47-55 under 35 U.S.C. 112, first paragraph, as containing subject matter which was not described in the specification in such a way as to reasonably convey to one skilled in the relevant art that the inventor(s), at the time the application was filed, had possession of the claimed invention in the Office action mailed 4/25/00 is maintained for reasons of record.

The claims are drawn to human cells comprising two recombinant nucleic acids, one comprising a Rad51 gene, and the second comprising a tumor suppressor gene. The specification

Art Unit: 1631

does not disclose human cells comprising the two claimed recombinant nucleic acids, nor does it disclose a method of using such cells. The instant specification discloses methods of using the claimed combination of nucleic acids for producing encoded proteins for use in binding assays on page 23 and for generating specific antisera for in situ staining on page 31. The specification discussed on pages 26-27 combinations of Rad51 and tumor suppressor genes for the purpose of expressing the genes individually so that the expressed proteins may be isolated and purified. The Rad51 and tumor suppressor proteins must be individually purified for use in binding assays and to generate antisera.

- 5. Claims 40-44 are rejected under 35 U.S.C. 112, first paragraph, as containing subject matter which was not described in the specification in such a way as to enable one skilled in the art to which it pertains, or with which it is most nearly connected, to make and/or use the invention for reasons of record.
- 6. It is brought to the applicant's attention that for the purposes of examination the phrase "pharmaceutical composition" is interpreted to mean a composition that can be used to provide a therapeutic benefit to a recipient of the composition.

Conclusion

7. This is a CPA of applicant's earlier Application No. 09/181027. All claims are drawn to the same invention claimed in the earlier application and could have been finally rejected on the grounds and art of record in the next Office action if they had been entered in the earlier application. Accordingly, **THIS ACTION IS MADE FINAL** even though it is a first action in this case. See MPEP § 706.07(b). Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a).

Application/Control Number: 09/181,027

Art Unit: 1631

Page 4

A shortened statutory period for reply to this final action is set to expire THREE

MONTHS from the mailing date of this action. In the event a first reply is filed within TWO

MONTHS of the mailing date of this final action and the advisory action is not mailed until after

the end of the THREE-MONTH shortened statutory period, then the shortened statutory period

will expire on the date the advisory action is mailed, and any extension fee pursuant to 37

CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no, however,

event will the statutory period for reply expire later than SIX MONTHS from the mailing date of

this final action.

Any inquiry concerning this communication or earlier communications from the

examiner should be directed to John S. Brusca whose telephone number is 703 308-4231. The

examiner can normally be reached on M-F 8:30-5:00.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's

supervisor, Michael Woodward can be reached on 708 308-4323. The fax phone numbers for

the organization where this application or proceeding is assigned are 703 746-5137 for regular

communications and 703 746-5137 for After Final communications.

Any inquiry of a general nature or relating to the status of this application or proceeding

should be directed to the receptionist whose telephone number is 703 308-4028.

John S. Brusca

Primary Examiner

Art Unit 1631

jsb

April 2, 2002